Company Overview - Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for endocrine diseases and endocrine-related tumors [4] - The company's lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors [4] - Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome [4] - All drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, addressing various endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, diabetes, obesity, and GPCR-targeted oncology indications [4] Upcoming Financial Results - Crinetics Pharmaceuticals will report first quarter 2025 financial results on May 8, 2025, after the market closes [1] - Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update [1] Conference Call Details - The conference call can be accessed via domestic dial-in number 1-833-470-1428 or international dial-in number 1-404-975-4839, with Conference ID: CRNXQ1 [2] - Participants are recommended to connect at least 15 minutes prior to the scheduled start of the call to ensure a timely connection [2] - The webcast will be archived on the Investor Relations section of the Crinetics website [3]

SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on April 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 124,950 shares of its common stock and granted an aggregate of 84,725 restricted stock unit ("RSU") awards to 26 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the "2021 ...

SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 124,950 shares of its common stock and granted an aggregate of 84,725 restricted stock unit (“RSU”) awards to 26 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 ...

I covered Crinetics Pharma (NASDAQ: CRNX ) back in 2023, when it was developing Paltusotine for acromegaly in a phase 3 trial. Now, they have positive data and a September 25 PDUFA date, so let us take a look.About the TPT ServiceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. For investors requiring ...

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment and long-term maintenance therapy of acromegaly, a serious, rare and progressive endocrine disorder characterized by consistently elevated levels of growth horm ...

Core Viewpoint - Crinetics Pharmaceuticals has granted stock options and restricted stock units (RSUs) to new employees as part of its 2021 Employment Inducement Incentive Award Plan to attract talent [1][2]. Group 1: Stock Options and RSUs - The Compensation Committee granted a total of 95,675 stock options to fifteen new non-executive employees and 80,000 to one new executive employee [1]. - Additionally, 40,775 RSUs were awarded to sixteen new non-executive employees and 52,000 to one new executive employee [1]. - The stock options have an exercise price of $33.75 per share, equal to the closing price of Crinetics' common stock on March 10, 2025 [2]. Group 2: Vesting Schedule - The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remaining shares vesting in 36 equal monthly installments [2]. - The RSUs will also vest over four years in equal annual installments starting on the one-year anniversary [2]. Group 3: Company Overview - Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on developing novel therapeutics for endocrine diseases and related tumors [3]. - The lead candidate, paltusotine, is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors [3]. - The company is also developing atumelnant, an oral ACTH antagonist for congenital adrenal hyperplasia and Cushing's disease [3].

Core Viewpoint - Crinetics Pharmaceuticals has granted stock options and restricted stock units (RSUs) to new employees as part of its 2021 Employment Inducement Incentive Award Plan to attract talent [1][2]. Group 1: Stock Options and RSUs - The Compensation Committee granted non-qualified stock options to purchase a total of 95,675 shares to fifteen new non-executive employees and 80,000 shares to one new executive employee [1]. - An aggregate of 40,775 RSUs was awarded to sixteen new non-executive employees and 52,000 RSUs to one new executive employee [1]. - The stock options have an exercise price of $33.75 per share, equal to the closing price of Crinetics' common stock on March 10, 2025 [2]. Group 2: Vesting Schedule - The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remaining shares vesting in 36 equal monthly installments [2]. - The RSUs will also vest over four years in equal annual installments starting on the one-year anniversary [2]. Group 3: Company Overview - Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on developing novel therapeutics for endocrine diseases and related tumors [3]. - The lead candidate, paltusotine, is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors [3]. - The company is also developing atumelnant, an oral ACTH antagonist for congenital adrenal hyperplasia and Cushing's disease [3].

Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX) Q4 2024 Results Conference Call February 27, 2025 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and Chief Executive Officer Isabel Kalofonos - Chief Commercial Officer Dana Pizzuti - Chief Medical and Development Officer Steve Betz - Founder & Chief Scientific Officer Marc Wilson - Chief Financial Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Tyler Van Buren - TD Cowen Joe Schwartz ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 f t 6055 Lusk Boulevard San Diego, California 92121 (Address of principal executive offices) (Zip code) Registrant's telephone number, including area code: (858) 450-6464 Securities registered pur ...

Financial Performance - Crinetics Pharmaceuticals reported a net loss of $80.6 million for Q4 2024, compared to a net loss of $60.1 million in Q4 2023, and a full-year net loss of $298.4 million versus $214.5 million in 2023[6][14]. - The company had no revenues for Q4 2024, while total revenues for the full year were $1.0 million, down from $4.0 million in 2023, primarily from the paltusotine licensing agreement[6][8][14]. - Research and development expenses increased to $66.6 million for Q4 2024 and $240.2 million for the full year, compared to $45.6 million and $168.5 million in 2023, driven by higher personnel costs and increased clinical activities[6][14]. - Crinetics has strengthened its balance sheet and expects cash used in operations to be between $340 million and $380 million for 2025[8][14]. Cash Position - Crinetics has a strong cash position of $1.4 billion as of December 31, 2024, up from $558.6 million a year earlier, providing a runway into 2029[6][8][14]. Development Pipeline - The company expects to initiate four late-stage trials and additional early-stage trials from its development pipeline in 2025[1][3]. - The company plans to file four novel IND applications in 2025 for development candidates nominated in 2024[5][6]. Regulatory Milestones - The FDA has set a PDUFA target action date of September 25, 2025, for the NDA of paltusotine for the treatment of acromegaly[1][5]. Clinical Results - Positive topline results were reported for the Phase 2 study of atumelnant in congenital adrenal hyperplasia, showing significant reductions in A4 levels[7][14]. Leadership Changes - Crinetics appointed new leadership, including Toby Schilke as Chief Financial Officer and Isabel Kalofonos as Chief Commercial Officer, to strengthen its organization ahead of product launches[4][6].